These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17482805)

  • 21. A novel derivatives of thiazol-4(5H)-one and their activity in the inhibition of 11β-hydroxysteroid dehydrogenase type 1.
    Studzińska R; Kołodziejska R; Kupczyk D; Płaziński W; Kosmalski T
    Bioorg Chem; 2018 Sep; 79():115-121. PubMed ID: 29738970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperazine sulfonamides as potent, selective, and orally available 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with efficacy in the rat cortisone-induced hyperinsulinemia model.
    Xiang J; Wan ZK; Li HQ; Ipek M; Binnun E; Nunez J; Chen L; McKew JC; Mansour TS; Xu X; Suri V; Tam M; Xing Y; Li X; Hahm S; Tobin J; Saiah E
    J Med Chem; 2008 Jul; 51(14):4068-71. PubMed ID: 18578516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
    Blum A; Favia AD; Maser E
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD; Kowalski TJ
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
    Hamilton BS; Himmelsbach F; Nar H; Schuler-Metz A; Krosky P; Guo J; Guo R; Meng S; Zhao Y; Lala DS; Zhuang L; Claremon DA; McGeehan GM
    Eur J Pharmacol; 2015 Jan; 746():50-5. PubMed ID: 25445047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Sutin L; Andersson S; Bergquist L; Castro VM; Danielsson E; James S; Henriksson M; Johansson L; Kaiser C; Flyrén K; Williams M
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4837-40. PubMed ID: 17600707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
    Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 11β-Hydroxysteroid dehydrogenase type 1 selective inhibitor BVT.2733 protects osteoblasts against endogenous glucocorticoid induced dysfunction.
    Wu L; Qi H; Zhong Y; Lv S; Yu J; Liu J; Wang L; Bi J; Kong X; Di W; Zha J; Liu F; Ding G
    Endocr J; 2013; 60(9):1047-58. PubMed ID: 23759754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
    Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
    Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
    J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
    Su X; Vicker N; Lawrence H; Smith A; Purohit A; Reed MJ; Potter BV
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):312-20. PubMed ID: 17493801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
    Zhang X; Zhou Z; Yang H; Chen J; Feng Y; Du L; Leng Y; Shen J
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4455-8. PubMed ID: 19564108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
    Xia G; You X; Liu L; Liu H; Wang J; Shi Y; Li P; Xiong B; Liu X; Shen J
    Eur J Med Chem; 2013 Apr; 62():1-10. PubMed ID: 23353742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Development by Lentiviral Screening Based on Computational Modeling.
    Liu H; Li L; Zhang C; Li H; Liu J; Tang C; Zhang Y; Wu D; Chu Y; Wu Y; Yuan X
    Pharmacology; 2018; 102(3-4):169-179. PubMed ID: 30099452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.
    Sun D; Wang Z; Caille S; DeGraffenreid M; Gonzalez-Lopez de Turiso F; Hungate R; Jaen JC; Jiang B; Julian LD; Kelly R; McMinn DL; Kaizerman J; Rew Y; Sudom A; Tu H; Ursu S; Walker N; Willcockson M; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2011 Jan; 21(1):405-10. PubMed ID: 21093258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
    Cooper MS; Stewart PM
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, molecular docking and in vitro evaluation of benzothiazole derivatives as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Cabrera Pérez LC; Padilla-Martínez II; Cruz A; Correa Basurto J; Miliar García Á; Hernández Zavala AA; Gómez López M; Rosales Hernández MC
    Mol Divers; 2020 Nov; 24(4):1-14. PubMed ID: 31664610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 1,4-diaryl-1,4-dihydropyrazines as novel 11β-HSD1 inhibitors.
    Duan X; Xin H; Yan H
    Biol Pharm Bull; 2014; 37(5):840-6. PubMed ID: 24790006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
    Saiah E
    Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.